Go Therapeutics gotherapeutics.com

GO Therapeutics solves the key challenge of tumor-specificity to bring more targeted immunotherapy to cancer patients. By making antibodies to hybrid antigens combining a tumor's up-regulated protein expression with a protein's aberrant glycosylation pattern, the company is able to increase tumor specificity. Its technology clears the hurdles for making drugs that are extremely specific to the cancer cell.

GO Therapeutics solves the key challenge of tumor-specificity to bring more targeted immunotherapy to cancer patients. By making antibodies to hybrid antigens combining a tumor's up-regulated protein expression with a protein's aberrant glycosylation...Show all

Company (Alive / Active)

All investors data 2 Investors

• Salubris Pharmaceuticals
• Undisclosed Investors